{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:39:44Z","timestamp":1784957984532,"version":"3.55.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pharmacotherapy of late-life depression (LLD) is characterized by clinical complexity. Older adults are living longer with multimorbidity, frailty and polypharmacy, and are taking more CNS-active medications and substances. These add to the risk and complexity of adding or changing depression treatment. At the same time, there are more medication options for depression and the use of many of them entails balancing potentials risks and benefits. As a result, the pharmacotherapy of LLD should be guided by tools such as algorithms or decision trees to maximize effectiveness and minimize risks of depression treatment. We propose an evidence-informed stepwise algorithm, based on three decades of clinical trials. With this algorithm, treatment starts with serotonin-selective reuptake inhibitors because of their safety and ease of use. If the patient does not respond, the next step is switching to serotonin-norepinephrine reuptake inhibitors, followed by augmentation (with aripiprazole as the preferred agent). For older patients who do not tolerate or do not respond to traditional pharmacotherapy, treatment options include transcranial magnetic stimulation, ketamine, or electroconvulsive therapy. Psychotherapy can be used in combination with antidepressants at any point in this algorithm. We also discuss the need for precision medicine research to improve treatment outcomes in LLD, presenting two approaches. The first is a \u201clock and key\u201d approach, in which some patients need a specific medication to treat their depression, which requires biotyping to predict. The second is a \u201csimple vs. complex depression\u201d approach, which posits that some with TRD have a more complex illness consisting of less intact brain structure and function and are unlikely to benefit from any traditional treatment; they require novel-mechanism treatments targeting their specific pathophysiology, such as impaired slow wave sleep or accelerated biological aging. In the coming years, we expect these two complementary approaches to improve the outcomes of the increasing population of older adults who suffer from depression.<\/jats:p>","DOI":"10.1038\/s41386-026-02338-w","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:40:12Z","timestamp":1771515612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine"],"prefix":"10.1038","author":[{"given":"Eric J.","family":"Lenze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan F.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Anne","family":"Gebara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-6129","authenticated-orcid":false,"given":"Ginger E.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-6450","authenticated-orcid":false,"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2338_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s40471-021-00274-5","volume":"8","author":"HE Barry","year":"2021","unstructured":"Barry HE, Hughes CM. An update on medication use in older adults: a narrative review. Curr Epidemiol Rep. 2021;8:108\u201315. https:\/\/doi.org\/10.1007\/s40471-021-00274-5.","journal-title":"Curr Epidemiol Rep"},{"key":"2338_CR2","doi-asserted-by":"publisher","first-page":"e6105","DOI":"10.1002\/gps.6105","volume":"39","author":"M Srifuengfung","year":"2024","unstructured":"Srifuengfung M, Lenze EJ, Roose SP, Brown PJ, Lavretsky H, Karp JF, et al. Alcohol and substance use in older adults with treatment-resistant depression. Int J Geriatr Psychiatry. 2024;39:e6105.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2338_CR3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jagp.2025.06.022","volume":"33","author":"K Conaty","year":"2025","unstructured":"Conaty K, Gujral S, McCarty E, Rapp E, Schweitzer N, Voineskos AN, et al. The relationship between subjective cognitive decline and objective cognitive performance in older adults with treatment-resistant late-life depression: the role of depression severity. Am J Geriatr Psychiatry. 2025;33:1346\u201353. https:\/\/doi.org\/10.1016\/j.jagp.2025.06.022.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR4","doi-asserted-by":"crossref","unstructured":"Cristancho P, Lenze EJ, Dixon D, Miller JP, Mulsant BH, Reynolds CF, et al. Executive function predicts antidepressant treatment noncompletion in late-life depression. J Clin Psychiatry. 2018;79:16m11371.","DOI":"10.4088\/JCP.16m11371"},{"key":"2338_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/CIA.S9088","volume":"5","author":"VM Wilkins","year":"2010","unstructured":"Wilkins VM, Kiosses D, Ravdin LD. Late-life depression with comorbid cognitive impairment and disability: nonpharmacological interventions. Research support, N.I.H., extramural. Clin Inter Aging. 2010;5:323\u201331. https:\/\/doi.org\/10.2147\/CIA.S9088.","journal-title":"Clin Inter Aging"},{"key":"2338_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1176\/appi.ajp.20230392","volume":"181","author":"NJ Ainsworth","year":"2024","unstructured":"Ainsworth NJ, Marawi T, Maslej MM, Blumberger DM, McAndrews MP, Perivolaris A, et al. Cognitive outcomes after antidepressant pharmacotherapy for late-life depression: a systematic review and meta-analysis. Am J Psychiatry. 2024;181:234\u201345. https:\/\/doi.org\/10.1176\/appi.ajp.20230392.","journal-title":"Am J Psychiatry"},{"key":"2338_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03851-3","volume":"23","author":"M Mo","year":"2025","unstructured":"Mo M, Abzhandadze T, Hoang MT, Sacuiu S, Jurado PG, Pereira JB, et al. Antidepressant use and cognitive decline in patients with dementia: a national cohort study. BMC Med. 2025;23:82. https:\/\/doi.org\/10.1186\/s12916-025-03851-3.","journal-title":"BMC Med"},{"key":"2338_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamapsychiatry.2017.2362","volume":"74","author":"LV Kessing","year":"2017","unstructured":"Kessing LV, Gerds TA, Knudsen NN, J\u00f8rgensen LF, Kristiansen SM, Voutchkova D, et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry. 2017;74:1005\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.2362.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bdi.12260","volume":"17","author":"AG Gildengers","year":"2015","unstructured":"Gildengers AG, Butters MA, Aizenstein HJ, Marron MM, Emanuel J, Anderson SJ, et al. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disord. 2015;17:248\u201356. https:\/\/doi.org\/10.1111\/bdi.12260.","journal-title":"Bipolar Disord"},{"key":"2338_CR10","doi-asserted-by":"publisher","first-page":"14968","DOI":"10.1073\/pnas.1107411108","volume":"108","author":"JR Cirrito","year":"2011","unstructured":"Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-{beta} levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108:14968\u201373. https:\/\/doi.org\/10.1073\/pnas.1107411108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2338_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14740338.2024.2418950","volume":"23","author":"H Conn","year":"2024","unstructured":"Conn H, Jankovic J. Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024;23:1503\u201313. https:\/\/doi.org\/10.1080\/14740338.2024.2418950.","journal-title":"Expert Opin Drug Saf"},{"key":"2338_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/JCP.0b013e3181bf4ea3","volume":"29","author":"H Uchida","year":"2009","unstructured":"Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009;29:571\u20135. https:\/\/doi.org\/10.1097\/JCP.0b013e3181bf4ea3.","journal-title":"J Clin Psychopharmacol"},{"key":"2338_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4140\/TCP.n.2018.83","volume":"33","author":"T Askins Bailey","year":"2018","unstructured":"Askins Bailey T, Panjwani S. Atypical antipsychotics in late-life and treatment-resistant depression. Consult Pharm. 2018;33:83\u201388. https:\/\/doi.org\/10.4140\/TCP.n.2018.83.","journal-title":"Consult Pharm"},{"key":"2338_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neubiorev.2017.01.032","volume":"75","author":"YP Bao","year":"2017","unstructured":"Bao YP, Han Y, Ma J, Wang RJ, Shi L, Wang TY, et al. Cooccurrence and bidirectional prediction of sleep disturbances and depression in older adults: meta-analysis and systematic review. Neurosci Biobehav Rev. 2017;75:257\u201373. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.01.032.","journal-title":"Neurosci Biobehav Rev"},{"key":"2338_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1017\/S1041610217001454","volume":"30","author":"MJ Li","year":"2018","unstructured":"Li MJ, Kechter A, Olmstead RE, Irwin MR, Black DS. Sleep and mood in older adults: coinciding changes in insomnia and depression symptoms. Int Psychogeriatr. 2018;30:431\u20135. https:\/\/doi.org\/10.1017\/S1041610217001454.","journal-title":"Int Psychogeriatr"},{"key":"2338_CR16","volume":"19","author":"KE Sprecher","year":"2017","unstructured":"Sprecher KE, Kofler M. Sleep in late-life depression. Curr Psychiatry Rep. 2017;19:73.","journal-title":"Curr Psychiatry Rep"},{"key":"2338_CR17","first-page":"626","volume":"257","author":"MI Boulos","year":"2019","unstructured":"Boulos MI, Machado ADS, Juthani N, Perlis ML, Feren A, Murray BJ. Polysomnographic characteristics in late-life depression: a systematic review and meta-analysis of studies with psychiatric controls and healthy controls. J Affect Disord. 2019;257:626\u201338.","journal-title":"J Affect Disord"},{"key":"2338_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jagp.2024.07.020","volume":"33","author":"MSB Mak","year":"2025","unstructured":"Mak MSB, Gebara MA, Lenze EJ, Blumberger DM, Brown PJ, Cristancho P, et al. Poor sleep is common in treatment-resistant late-life depression and associated with poorer antidepressant response: findings from the OPTIMUM clinical trial. Am J Geriatr Psychiatry. 2025;33:63\u201372. https:\/\/doi.org\/10.1016\/j.jagp.2024.07.020.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR19","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.2174\/138161212803523608","volume":"18","author":"A Wichniak","year":"2012","unstructured":"Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18:5802\u201317. https:\/\/doi.org\/10.2174\/138161212803523608.","journal-title":"Curr Pharm Des"},{"key":"2338_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMcp2305655","volume":"391","author":"CM Morin","year":"2024","unstructured":"Morin CM, Buysse DJ. Management of insomnia. N Engl J Med. 2024;391:247\u201358. https:\/\/doi.org\/10.1056\/NEJMcp2305655.","journal-title":"N Engl J Med"},{"key":"2338_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.mayocp.2025.02.005","volume":"100","author":"LJ Klugherz","year":"2025","unstructured":"Klugherz LJ, Mansukhani MP, Kolla BP. Effects of commonly prescribed medications on sleep: a review of the literature. Mayo Clin Proc. 2025;100:856\u201367. https:\/\/doi.org\/10.1016\/j.mayocp.2025.02.005.","journal-title":"Mayo Clin Proc"},{"key":"2338_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/JCP.0000000000000329","volume":"35","author":"S Alberti","year":"2015","unstructured":"Alberti S, Chiesa A, Andrisano C, Serretti A. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol. 2015;35:296\u2013303. https:\/\/doi.org\/10.1097\/JCP.0000000000000329.","journal-title":"J Clin Psychopharmacol"},{"key":"2338_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamainternmed.2016.9225","volume":"177","author":"DT Maust","year":"2017","unstructured":"Maust DT, Gerlach LB, Gibson A, Kales HC, Blow FC, Olfson M. Trends in central nervous system\u2013active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med. 2017;177:583\u20135. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9225.","journal-title":"JAMA Intern Med"},{"key":"2338_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","volume":"28","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28:287\u2013300. https:\/\/doi.org\/10.1016\/j.cger.2012.01.008.","journal-title":"Clin Geriatr Med"},{"key":"2338_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archgenpsychiatry.2010.184","volume":"68","author":"CF Reynolds III","year":"2011","unstructured":"Reynolds CF III, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011;68:51\u201360. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.184.","journal-title":"Arch Gen Psychiatry"},{"key":"2338_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.2018.6741","volume":"319","author":"DM Qato","year":"2018","unstructured":"Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319:2289\u201398. https:\/\/doi.org\/10.1001\/jama.2018.6741.","journal-title":"JAMA"},{"key":"2338_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1176\/appi.ps.201900551","volume":"71","author":"NG Choi","year":"2020","unstructured":"Choi NG, Marti CN, Kunik ME. Predictors of CNS-active medication use and polypharmacy among homebound older adults with depression. Psychiatr Serv. 2020;71:847\u201350. https:\/\/doi.org\/10.1176\/appi.ps.201900551.","journal-title":"Psychiatr Serv"},{"key":"2338_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/psyg.13102","volume":"24","author":"N Kayahan Satis","year":"2024","unstructured":"Kayahan Satis N, Naharci MI. Investigating the association of anticholinergic burden with depression in older adults: a cross-sectional study. Psychogeriatrics. 2024;24:597\u2013604. https:\/\/doi.org\/10.1111\/psyg.13102.","journal-title":"Psychogeriatrics"},{"key":"2338_CR29","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1007\/s11606-025-09499-2","volume":"40","author":"E Brunner","year":"2025","unstructured":"Brunner E, Chen CA, Klein T, Maust D, Mazer-Amirshahi M, Mecca M, et al. Joint clinical practice guideline on benzodiazepine tapering: considerations when risks outweigh benefits. J Gen Intern Med. 2025;40:2814\u201359. https:\/\/doi.org\/10.1007\/s11606-025-09499-2.","journal-title":"J Gen Intern Med"},{"key":"2338_CR30","doi-asserted-by":"publisher","first-page":"e259375","DOI":"10.1001\/jamanetworkopen.2025.9375","volume":"8","author":"AM Linsky","year":"2025","unstructured":"Linsky AM, Motala A, Booth M, Lawson E, Shekelle PG. Deprescribing in community-dwelling older adults: a systematic review and meta-analysis. JAMA Netw Open. 2025;8:e259375. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.9375.","journal-title":"JAMA Netw Open"},{"key":"2338_CR31","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s11606-020-06493-8","volume":"36","author":"EE Hahn","year":"2021","unstructured":"Hahn EE, Munoz-Plaza CE, Lee EA, Luong TQ, Mittman BS, Kanter MH, et al. Patient and physician perspectives of deprescribing potentially inappropriate medications in older adults with a history of falls: a qualitative study. J Gen Intern Med. 2021;36:3015\u201322. https:\/\/doi.org\/10.1007\/s11606-020-06493-8.","journal-title":"J Gen Intern Med"},{"key":"2338_CR32","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317. https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905.","journal-title":"Am J Psychiatry"},{"key":"2338_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cger.2014.05.002","volume":"30","author":"BH Mulsant","year":"2014","unstructured":"Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30:517\u201334. https:\/\/doi.org\/10.1016\/j.cger.2014.05.002.","journal-title":"Clin Geriatr Med"},{"key":"2338_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/gps.465","volume":"16","author":"BH Mulsant","year":"2001","unstructured":"Mulsant BH, Alexopoulos GS, Reynolds CF, Katz IR, Abrams R, Oslin D, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry. 2001;16:585\u201392. https:\/\/doi.org\/10.1002\/gps.465.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2338_CR35","doi-asserted-by":"crossref","unstructured":"Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP, Ross RW. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract 2001;7:361\u2013376.","DOI":"10.1097\/00131746-200111000-00003"},{"key":"2338_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/neu.2017.39","volume":"30","author":"VS Pereira","year":"2018","unstructured":"Pereira VS, Hiroaki-Sato VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatr. 2018;30:307\u201322. https:\/\/doi.org\/10.1017\/neu.2017.39.","journal-title":"Acta Neuropsychiatr"},{"key":"2338_CR37","first-page":"83","volume":"29","author":"CF Reynolds 3rd","year":"1993","unstructured":"Reynolds CF 3rd, Lebowitz BD, Schneider LS. The NIH consensus development conference on the diagnosis and treatment of depression in late life: an overview. Psychopharmacol Bull. 1993;29:83\u20135.","journal-title":"Psychopharmacol Bull"},{"key":"2338_CR38","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1097\/01.psy.0000163455.43226.bf","volume":"67","author":"SP Roose","year":"2005","unstructured":"Roose SP, Miyazaki M. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med. 2005;67:S54\u20137. https:\/\/doi.org\/10.1097\/01.psy.0000163455.43226.bf.","journal-title":"Psychosom Med"},{"key":"2338_CR39","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1001\/jama.1992.03490240049035","volume":"268","author":"S Kapur","year":"1992","unstructured":"Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992;268:3441\u20135.","journal-title":"JAMA"},{"key":"2338_CR40","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","volume":"56","author":"ML Chew","year":"2008","unstructured":"Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56:1333\u201341. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01737.x.","journal-title":"J Am Geriatr Soc"},{"key":"2338_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JGP.0b013e3181591c09","volume":"16","author":"A Bose","year":"2008","unstructured":"Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16:14\u201320. https:\/\/doi.org\/10.1097\/JGP.0b013e3181591c09.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00228-017-2219-1","volume":"73","author":"N Pruckner","year":"2017","unstructured":"Pruckner N, Holthoff-Detto V. Antidepressant pharmacotherapy in old-age depression-a review and clinical approach. Eur J Clin Pharm. 2017;73:661\u20137. https:\/\/doi.org\/10.1007\/s00228-017-2219-1.","journal-title":"Eur J Clin Pharm"},{"key":"2338_CR43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00019442-200111000-00009","volume":"9","author":"BH Mulsant","year":"2001","unstructured":"Mulsant BH, Pollock BG, Nebes R, Miller MD, Sweet RA, Stack J, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry. 2001;9:406\u201314.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1520-6394(2001)13:1<38::AID-DA6>3.0.CO;2-7","volume":"13","author":"GM Bump","year":"2001","unstructured":"Bump GM, Mulsant BH, Pollock BG, Mazumdar S, Begley AE, Dew MA, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13:38\u201344.","journal-title":"Depress Anxiety"},{"key":"2338_CR45","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJMoa052619","volume":"354","author":"CF Reynolds III","year":"2006","unstructured":"Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130\u20138. https:\/\/doi.org\/10.1056\/NEJMoa052619.","journal-title":"N Engl J Med"},{"key":"2338_CR46","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.4088\/JCP.v65n1208","volume":"65","author":"EM Whyte","year":"2004","unstructured":"Whyte EM, Basinski J, Farhi P, Dew MA, Begley A, Mulsant BH, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1634\u201341.","journal-title":"J Clin Psychiatry"},{"key":"2338_CR47","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","volume":"28","author":"LM Hesse","year":"2000","unstructured":"Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176\u201383.","journal-title":"Drug Metab Dispos"},{"key":"2338_CR48","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/0091270005280297","volume":"45","author":"FE Lotrich","year":"2005","unstructured":"Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharm. 2005;45:1106\u201322.","journal-title":"J Clin Pharm"},{"key":"2338_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharm Ther. 2023;114:51\u201368. https:\/\/doi.org\/10.1002\/cpt.2903.","journal-title":"Clin Pharm Ther"},{"key":"2338_CR50","first-page":"109","volume":"33","author":"JP Foglia","year":"1997","unstructured":"Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull. 1997;33:109\u201312.","journal-title":"Psychopharmacol Bull"},{"key":"2338_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jagp.2019.11.001","volume":"28","author":"A Iaboni","year":"2020","unstructured":"Iaboni A, Mulsant BH. Why do older adults taking antidepressants fall? Am J Geriatr Psychiatry. 2020;28:285\u20137. https:\/\/doi.org\/10.1016\/j.jagp.2019.11.001.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR52","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.biopsych.2023.05.018","volume":"94","author":"T Marawi","year":"2023","unstructured":"Marawi T, Zhukovsky P, Rashidi-Ranjbar N, Bowie CR, Brooks H, Fischer CE, et al. Brain-cognition associations in older patients with remitted major depressive disorder or mild cognitive impairment: a multivariate analysis of gray and white matter integrity. Biol Psychiatry. 2023;94:913\u201323. https:\/\/doi.org\/10.1016\/j.biopsych.2023.05.018.","journal-title":"Biol Psychiatry"},{"key":"2338_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jagp.2022.08.003","volume":"31","author":"E Mastrobattista","year":"2023","unstructured":"Mastrobattista E, Lenze EJ, Reynolds CF, Mulsant BH, Wetherell J, Wu GF, et al. Late-life depression is associated with increased levels of GDF-15, a pro-aging mitokine. Am J Geriatr Psychiatry. 2023;31:1\u20139. https:\/\/doi.org\/10.1016\/j.jagp.2022.08.003.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/jamapsychiatry.2024.3241","volume":"82","author":"TK Rajji","year":"2025","unstructured":"Rajji TK, Bowie CR, Herrmann N, Pollock BG, Lanct\u00f4t KL, Kumar S, et al. Slowing cognitive decline in major depressive disorder and mild cognitive impairment: a randomized clinical trial. JAMA Psychiatry. 2025;82:12\u201321. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3241.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR55","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41386-022-01308-2","volume":"48","author":"N Rashidi-Ranjbar","year":"2023","unstructured":"Rashidi-Ranjbar N, Rajji TK, Hawco C, Kumar S, Herrmann N, Mah L, et al. Association of functional connectivity of the executive control network or default mode network with cognitive impairment in older adults with remitted major depressive disorder or mild cognitive impairment. Neuropsychopharmacology. 2023;48:468\u201377. https:\/\/doi.org\/10.1038\/s41386-022-01308-2.","journal-title":"Neuropsychopharmacology"},{"key":"2338_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s44220-023-00033-z","volume":"1","author":"J Seitz-Holland","year":"2023","unstructured":"Seitz-Holland J, Mulsant BH, Reynolds CF 3rd, Blumberger DM, Karp JF, Butters MA, et al. Major depression, physical health and molecular senescence markers abnormalities. Nat Ment Health. 2023;1:200\u20139. https:\/\/doi.org\/10.1038\/s44220-023-00033-z.","journal-title":"Nat Ment Health"},{"key":"2338_CR57","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002512-200118050-00006","volume":"18","author":"LK Solai","year":"2001","unstructured":"Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging. 2001;18:355\u201368. https:\/\/doi.org\/10.2165\/00002512-200118050-00006.","journal-title":"Drugs Aging"},{"key":"2338_CR58","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1176\/ajp.155.8.1110","volume":"155","author":"BG Pollock","year":"1998","unstructured":"Pollock BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Mazumdar S, et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry. 1998;155:1110\u20132. https:\/\/doi.org\/10.1176\/ajp.155.8.1110.","journal-title":"Am J Psychiatry"},{"key":"2338_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.osep.2025.03.001","volume":"6","author":"C Guasch","year":"2025","unstructured":"Guasch C, Schulte VP, Rojas-Velasquez D. Association of antidepressants and apathy in the geriatric population: a systematic literature review. Am J Geriatr Psychiatry: Open Sci, Educ, Pract. 2025;6:24\u201338. https:\/\/doi.org\/10.1016\/j.osep.2025.03.001.","journal-title":"Am J Geriatr Psychiatry: Open Sci, Educ, Pract"},{"key":"2338_CR60","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/089198879400700412","volume":"7","author":"R Druckenbrod","year":"1994","unstructured":"Druckenbrod R, Mulsant BH. Fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion: a geriatric case report and a review of the literature. J Geriatr Psychiatry Eur. 1994;7:254\u20136. https:\/\/doi.org\/10.1177\/089198879400700412.","journal-title":"J Geriatr Psychiatry Eur"},{"key":"2338_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/archinte.164.3.327","volume":"164","author":"TJ Fabian","year":"2004","unstructured":"Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004;164:327\u201332. https:\/\/doi.org\/10.1001\/archinte.164.3.327.","journal-title":"Arch Intern Med"},{"key":"2338_CR62","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.amjmed.2006.05.005","volume":"119","author":"A Upadhyay","year":"2006","unstructured":"Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30\u20135. https:\/\/doi.org\/10.1016\/j.amjmed.2006.05.005.","journal-title":"Am J Med"},{"key":"2338_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4140\/TCP.n.2016.139","volume":"31","author":"TS Viramontes","year":"2016","unstructured":"Viramontes TS, Truong H, Linnebur SA. Antidepressant-induced hyponatremia in older adults. Consult Pharm. 2016;31:139\u201350. https:\/\/doi.org\/10.4140\/TCP.n.2016.139.","journal-title":"Consult Pharm"},{"key":"2338_CR64","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1080\/14656566.2021.1921736","volume":"22","author":"R Brender","year":"2021","unstructured":"Brender R, Mulsant BH, Blumberger DM. An update on antidepressant pharmacotherapy in late-life depression. Expert Opin Pharmacother. 2021;22:1909\u201317.","journal-title":"Expert Opin Pharmacother"},{"key":"2338_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.ajkd.2016.08.020","volume":"69","author":"S Gandhi","year":"2017","unstructured":"Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, et al. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. Am J Kidney Dis. 2017;69:87\u201396. https:\/\/doi.org\/10.1053\/j.ajkd.2016.08.020.","journal-title":"Am J Kidney Dis"},{"key":"2338_CR66","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1176\/appi.ajp.158.12.2074","volume":"158","author":"EM Whyte","year":"2001","unstructured":"Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry. 2001;158:2074\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.158.12.2074.","journal-title":"Am J Psychiatry"},{"key":"2338_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/02698811231218955","volume":"38","author":"YH Li","year":"2024","unstructured":"Li YH, Hang LW, Muo CH, Chen SJ, Chen PC. Dose of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding in older adults. J Psychopharmacol. 2024;38:137\u201344. https:\/\/doi.org\/10.1177\/02698811231218955.","journal-title":"J Psychopharmacol"},{"key":"2338_CR68","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1532-5415.2010.02826.x","volume":"58","author":"S Nahon","year":"2010","unstructured":"Nahon S, Pariente A, Faroux R, R\u00e9my AJ, Nouel O. Prognosis of upper gastrointestinal bleeding in the oldest-old patients: a post-hoc analysis of a prospective study. J Am Geriatr. Soc. 2010;58:989\u201390. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02826.x.","journal-title":"J Am Geriatr. Soc"},{"key":"2338_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phrs.2016.08.017","volume":"118","author":"S Laporte","year":"2017","unstructured":"Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19\u201332. https:\/\/doi.org\/10.1016\/j.phrs.2016.08.017.","journal-title":"Pharmacol Res"},{"key":"2338_CR70","first-page":"34","volume":"21","author":"N Pothen","year":"2024","unstructured":"Pothen N, Patel P, Jafri A. Selective serotonin reuptake inhibitors and bleeding risk in the geriatric population. Innov Clin Neurosci. 2024;21:34\u20137.","journal-title":"Innov Clin Neurosci"},{"key":"2338_CR71","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.319.7217.1106","volume":"319","author":"FJ de Abajo","year":"1999","unstructured":"de Abajo FJ, Rodr\u00edguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106\u20139. https:\/\/doi.org\/10.1136\/bmj.319.7217.1106.","journal-title":"BMJ"},{"key":"2338_CR72","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","volume":"55","author":"SA Williams","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR. Economic burden of osteoporosis-related fractures in the US medicare population. Ann Pharmacother. 2021;55:821\u20139. https:\/\/doi.org\/10.1177\/1060028020970518.","journal-title":"Ann Pharmacother"},{"key":"2338_CR73","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa2204462","volume":"388","author":"EJ Lenze","year":"2023","unstructured":"Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF, Blumberger DM, et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N Engl J Med. 2023;388:1067\u201379. https:\/\/doi.org\/10.1056\/NEJMoa2204462.","journal-title":"N Engl J Med"},{"key":"2338_CR74","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jagp.2014.11.004","volume":"23","author":"MA Gebara","year":"2015","unstructured":"Gebara MA, Lipsey KL, Karp JF, Nash MC, Iaboni A, Lenze EJ. Cause or effect? Selective serotonin reuptake inhibitors and falls in older adults: a systematic review. Am J Geriatr Psychiatry. 2015;23:1016\u201328. https:\/\/doi.org\/10.1016\/j.jagp.2014.11.004.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR75","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jgs.12945","volume":"62","author":"MA Gebara","year":"2014","unstructured":"Gebara MA, Shea ML, Lipsey KL, Teitelbaum SL, Civitelli R, M\u00fcller DJ, et al. Depression, antidepressants, and bone health in older adults: a systematic review. J Am Geriatr Soc. 2014;62:1434\u201341. https:\/\/doi.org\/10.1111\/jgs.12945.","journal-title":"J Am Geriatr Soc"},{"key":"2338_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1176\/appi.ajp.2008.07081340","volume":"165","author":"C Andreescu","year":"2008","unstructured":"Andreescu C, Mulsant BH, Houck PR, Whyte EM, Mazumdar S, Dombrovski AY, et al. Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry. 2008;165:855\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.2008.07081340.","journal-title":"Am J Psychiatry"},{"key":"2338_CR77","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/ebmental-2022-300479","volume":"25","author":"HK Kim","year":"2022","unstructured":"Kim HK, Blumberger DM, Karp JF, Lenze E, Reynolds CF, Mulsant BH. Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment. Evid Based Ment Health. 2022;25:156\u201362. https:\/\/doi.org\/10.1136\/ebmental-2022-300479.","journal-title":"Evid Based Ment Health"},{"key":"2338_CR78","doi-asserted-by":"crossref","unstructured":"Husain MI, Nigah Z, Ansari SUH, Khoso AB, Kiran T, Umer M, et al. Measurement-based care to enhance antidepressant treatment outcomes in major depressive disorder: a randomized clinical trial. JAMA Netw Open. 2025;8:e2529427.","DOI":"10.1001\/jamanetworkopen.2025.29427"},{"key":"2338_CR79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1055\/a-2508-5757","volume":"58","author":"E Tavakoli","year":"2025","unstructured":"Tavakoli E, Xiang A, Husain MI, Blumberger DM, Kloiber S, Mueller DJ, et al. Challenges related to the implementation of measurement-based care for the treatment of major depressive disorder: a feasibility study. Pharmacopsychiatry. 2025;58:170\u20137. https:\/\/doi.org\/10.1055\/a-2508-5757.","journal-title":"Pharmacopsychiatry"},{"key":"2338_CR80","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/jgs.15966","volume":"67","author":"DM Sobieraj","year":"2019","unstructured":"Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, et al. Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc. 2019;67:1571\u201381. https:\/\/doi.org\/10.1111\/jgs.15966.","journal-title":"J Am Geriatr Soc"},{"key":"2338_CR81","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4088\/jcp.v58n1006","volume":"58","author":"LK Solai","year":"1997","unstructured":"Solai LK, Mulsant BH, Pollock BG, Sweet RA, Rosen J, Yu K, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry. 1997;58:440\u20133. https:\/\/doi.org\/10.4088\/jcp.v58n1006.","journal-title":"J Clin Psychiatry"},{"key":"2338_CR82","doi-asserted-by":"publisher","first-page":"103849","DOI":"10.1016\/j.brat.2021.103849","volume":"143","author":"SD Hollon","year":"2021","unstructured":"Hollon SD, Andrews PW, Singla DR, Maslej MM, Mulsant BH. Evolutionary theory and the treatment of depression: it is all about the squids and the sea bass. Behav Res Ther. 2021;143:103849 https:\/\/doi.org\/10.1016\/j.brat.2021.103849.","journal-title":"Behav Res Ther"},{"key":"2338_CR83","doi-asserted-by":"publisher","unstructured":"Buchalter ELF, Oughli HA, Lenze EJ, Dixon D, Miller JP, Blumberger DM, et al. Predicting remission in late-life major depression: a clinical algorithm based upon past treatment history. J Clin Psychiatry. 2019;80. https:\/\/doi.org\/10.4088\/JCP.18m12483.","DOI":"10.4088\/JCP.18m12483"},{"key":"2338_CR84","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jpsychires.2024.05.046","volume":"176","author":"HA Sackeim","year":"2024","unstructured":"Sackeim HA, Aaronson ST, Bunker MT, Conway CR, George MS, McAlister-Williams RH, et al. Update on the assessment of resistance to antidepressant treatment: rationale for the antidepressant treatment history form: short form-2 (ATHF-SF2). J Psychiatr Res. 2024;176:325\u201337. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.05.046.","journal-title":"J Psychiatr Res"},{"key":"2338_CR85","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jagp.2024.09.018","volume":"33","author":"NJ Ainsworth","year":"2024","unstructured":"Ainsworth NJ, Oughli H, Lavretsky H, Blumberger DM, Brown PJ, Butters MA, et al. The cognitive profile of older adults with treatment-resistant depression: an analysis of the OPTIMUM randomized controlled trial. Am J Geriatr Psychiatry. 2024;33:361\u201371. https:\/\/doi.org\/10.1016\/j.jagp.2024.09.018.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR86","doi-asserted-by":"publisher","first-page":"e2219678","DOI":"10.1001\/jamanetworkopen.2022.19678","volume":"5","author":"BS Diniz","year":"2022","unstructured":"Diniz BS, Mulsant BH, Reynolds CF 3rd, Blumberger DM, Karp JF, Butters MA, et al. Association of molecular senescence markers in late-life depression with clinical characteristics and treatment outcome. JAMA Netw Open. 2022;5:e2219678 https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.19678.","journal-title":"JAMA Netw Open"},{"key":"2338_CR87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41397-024-00351-0","volume":"24","author":"SSM Elsheikh","year":"2024","unstructured":"Elsheikh SSM, Marshe VS, Men X, Islam F, Gon\u00e7alves VF, Par\u00e9 G, et al. Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study. Pharmacogenomics J. 2024;24:38. https:\/\/doi.org\/10.1038\/s41397-024-00351-0.","journal-title":"Pharmacogenomics J"},{"key":"2338_CR88","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/01.jcp.0000161498.81137.12","volume":"25","author":"AG Gildengers","year":"2005","unstructured":"Gildengers AG, Houck PR, Mulsant BH, Dew MA, Aizenstein HJ, Jones BL, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharmacol. 2005;25:S8\u201313. https:\/\/doi.org\/10.1097\/01.jcp.0000161498.81137.12.","journal-title":"J Clin Psychopharmacol"},{"key":"2338_CR89","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/appi.ps.201400480","volume":"66","author":"CA Hall","year":"2015","unstructured":"Hall CA, Simon KM, Lenze EJ, Dew MA, Begley A, Butters MA, et al. Depression remission rates among older black and white adults: analyses from the IRL-GREY trial. Psychiatr Serv. 2015;66:1303\u201311. https:\/\/doi.org\/10.1176\/appi.ps.201400480.","journal-title":"Psychiatr Serv"},{"key":"2338_CR90","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamapsychiatry.2015.3447","volume":"73","author":"SH Kaneriya","year":"2016","unstructured":"Kaneriya SH, Robbins-Welty GA, Smagula SF, Karp JF, Butters MA, Lenze EJ, et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiatry. 2016;73:329\u201336. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.3447.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR91","doi-asserted-by":"crossref","unstructured":"Kim HK, Karp JF, Lavretsky H, Blumberger DM, Brown PJ, Flint AJ, et al. Moderators of antidepressant augmentation vs. switch in the OPTIMUM randomized controlled trial. Br J Psychiatry. 2025;227:1\u20138.","DOI":"10.1192\/bjp.2025.125"},{"key":"2338_CR92","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/da.22424","volume":"32","author":"WK Silverstein","year":"2015","unstructured":"Silverstein WK, Noda Y, Barr MS, Vila-Rodriguez F, Rajji TK, Fitzgerald PB, et al. Neurobiological predictors of response to dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation in depression: a systematic review. Depress Anxiety. 2015;32:871\u201391. https:\/\/doi.org\/10.1002\/da.22424.","journal-title":"Depress Anxiety"},{"key":"2338_CR93","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/09540261.2020.1765748","volume":"32","author":"B Carter","year":"2020","unstructured":"Carter B, Strawbridge R, Husain MI, Jones B, Short R, Cleare AJ, et al. Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis. Int Rev Psychiatry. 2020;32:477\u201390. https:\/\/doi.org\/10.1080\/09540261.2020.1765748.","journal-title":"Int Rev Psychiatry"},{"key":"2338_CR94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1176\/appi.ajp.2011.10081165","volume":"168","author":"C Cooper","year":"2011","unstructured":"Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168:681\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10081165.","journal-title":"Am J Psychiatry"},{"key":"2338_CR95","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","volume":"386","author":"EJ Lenze","year":"2015","unstructured":"Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:2404\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(15)00308-6.","journal-title":"Lancet"},{"key":"2338_CR96","unstructured":"Bender DA, Mulsant BH, Lavretsky H, et al. Risk factors for falls in older depressed adults treated with bupropion: an analysis of the OPTIMUM randomized clinical trial (In Press). J Gen Intern Med."},{"key":"2338_CR97","doi-asserted-by":"crossref","unstructured":"Oughli HA, Ainsworth NJ, Butters MA, Brown PJ, Gebara MA, Gettinger TR, et al. Cognitive changes in older adults receiving pharmacotherapy for treatment-resistant depression: a secondary analysis of the OPTIMUM randomized controlled trial. Lancet Healthy Longev. 2025;6:100767.","DOI":"10.1016\/j.lanhl.2025.100767"},{"key":"2338_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","volume":"74","author":"CR Conway","year":"2017","unstructured":"Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017;74:9\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.2586.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR99","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jagp.2022.11.013","volume":"31","author":"HA Oughli","year":"2023","unstructured":"Oughli HA, Gebara MA, Ciarleglio A, Lavretsky H, Brown PJ, Flint AJ, et al. Intravenous ketamine for late-life treatment-resistant depression: a pilot study of tolerability, safety, clinical benefits, and effect on cognition. Am J Geriatr Psychiatry. 2023;31:210\u201321. https:\/\/doi.org\/10.1016\/j.jagp.2022.11.013.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5964","volume":"38","author":"B Vanderschelden","year":"2023","unstructured":"Vanderschelden B, Gebara MA, Oughli HA, Butters MA, Brown PJ, Farber NB, et al. Change in patient-centered outcomes of psychological well-being, sleep, and suicidality following treatment with intravenous ketamine for late-life treatment-resistant depression. Int J Geriatr Psychiatry. 2023;38:e5964. https:\/\/doi.org\/10.1002\/gps.5964.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2338_CR101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jagp.2016.02.053","volume":"24","author":"S Kumar","year":"2016","unstructured":"Kumar S, Mulsant BH, Liu AY, Blumberger DM, Daskalakis ZJ, Rajji TK. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24:547\u201365. https:\/\/doi.org\/10.1016\/j.jagp.2016.02.053.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR102","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/acps.12815","volume":"136","author":"DM Blumberger","year":"2017","unstructured":"Blumberger DM, Seitz DP, Herrmann N, Kirkham JG, Ng R, Reimer C, et al. Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample. Acta Psychiatr Scand. 2017;136:583\u201393. https:\/\/doi.org\/10.1111\/acps.12815.","journal-title":"Acta Psychiatr Scand"},{"key":"2338_CR103","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1176\/ajp.156.12.1865","volume":"156","author":"JD Tew Jr","year":"1999","unstructured":"Tew JD Jr, Mulsant BH, Haskett RF, Prudic J, Thase ME, Crowe RR, et al. Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry. 1999;156:1865\u201370.","journal-title":"Am J Psychiatry"},{"key":"2338_CR104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1017\/S1041610206224384","volume":"19","author":"AY Dombrovski","year":"2007","unstructured":"Dombrovski AY, Mulsant BH. The evidence for electroconvulsive therapy (ECT) in the treatment of severe late-life depression. ECT: the preferred treatment for severe depression in late life. Consensus Development Conference Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\u2019t. Int Psychogeriatr. 2007;19:10\u20134. https:\/\/doi.org\/10.1017\/S1041610206224384.","journal-title":"Int Psychogeriatr"},{"key":"2338_CR105","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/JCP.0000000000001354","volume":"41","author":"DA Patel","year":"2021","unstructured":"Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, et al. Pharmacotherapy prescriptions for relapse prevention of psychotic depression after electroconvulsive therapy. J Clin Psychopharmacol. 2021;41:196\u20139. https:\/\/doi.org\/10.1097\/JCP.0000000000001354.","journal-title":"J Clin Psychopharmacol"},{"key":"2338_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2020.101908","volume":"82","author":"SC Hayes","year":"2020","unstructured":"Hayes SC, Hofmann SG, Ciarrochi J. A process-based approach to psychological diagnosis and treatment:The conceptual and treatment utility of an extended evolutionary meta model. Clin Psychol Rev. 2020;82:101908. https:\/\/doi.org\/10.1016\/j.cpr.2020.101908.","journal-title":"Clin Psychol Rev"},{"key":"2338_CR107","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/gps.2443","volume":"25","author":"CF Reynolds III","year":"2010","unstructured":"Reynolds CF III, Dew MA, Martire LM, Miller MD, Cyranowski JM, Lenze E, et al. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry. 2010;25:1134\u201341. https:\/\/doi.org\/10.1002\/gps.2443.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2338_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1616925","volume":"13","author":"J Zeng","year":"2025","unstructured":"Zeng J, Wang H. The impact of high-intensity exercise on patients with depression: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2025;13:1616925. https:\/\/doi.org\/10.3389\/fpubh.2025.1616925.","journal-title":"Front Public Health"},{"key":"2338_CR109","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.4088\/JCP.16m10947","volume":"78","author":"JL Wetherell","year":"2017","unstructured":"Wetherell JL, Hershey T, Hickman S, Tate SR, Dixon D, Bower ES, et al. Mindfulness-based stress reduction for older adults with stress disorders and neurocognitive difficulties: a randomized controlled trial. J Clin Psychiatry. 2017;78:e734\u2013e743. https:\/\/doi.org\/10.4088\/JCP.16m10947.","journal-title":"J Clin Psychiatry"},{"key":"2338_CR110","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.281.1.39","volume":"281","author":"CF Reynolds III","year":"1999","unstructured":"Reynolds CF III, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39\u201345.","journal-title":"JAMA"},{"key":"2338_CR111","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jama.291.9.1081","volume":"291","author":"ML Bruce","year":"2004","unstructured":"Bruce ML, Ten Have TR, Reynolds CF 3rd, Katz II, Schulberg HC, Mulsant BH, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291:1081\u201391. https:\/\/doi.org\/10.1001\/jama.291.9.1081.","journal-title":"JAMA"},{"key":"2338_CR112","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1001\/jama.288.22.2836","volume":"288","author":"J Un\u00fctzer","year":"2002","unstructured":"Un\u00fctzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836\u201345.","journal-title":"JAMA"},{"key":"2338_CR113","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00228-023-03563-8","volume":"79","author":"M Kato","year":"2023","unstructured":"Kato M, Baba H, Takekita Y, Naito M, Koshikawa Y, Bandou H, et al. Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. Eur J Clin Pharm. 2023;79:1515\u201324. https:\/\/doi.org\/10.1007\/s00228-023-03563-8.","journal-title":"Eur J Clin Pharm"},{"key":"2338_CR114","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1176\/appi.ajp.2019.19050561","volume":"177","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Stevens A, Waring JD, Pham VT, Haddad R, Shimony J, et al. Augmenting computerized cognitive training with vortioxetine for age-related cognitive decline: a randomized controlled trial. Am J Psychiatry. 2020;177:548\u201355. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19050561.","journal-title":"Am J Psychiatry"},{"key":"2338_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02343-3","volume":"13","author":"Y Izumi","year":"2023","unstructured":"Izumi Y, Reiersen AM, Lenze EJ, Mennerick SJ, Zorumski CF. SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids. Transl Psychiatry. 2023;13:39. https:\/\/doi.org\/10.1038\/s41398-023-02343-3.","journal-title":"Transl Psychiatry"},{"key":"2338_CR116","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/13872877251340084","volume":"106","author":"E Cumbo","year":"2025","unstructured":"Cumbo E, Migliore D. Differential effects of antidepressants on cognition in Alzheimer\u2019s disease with depression: a sub-group analysis of an open-label, observational study. J Alzheimer\u2019s Dis. 2025;106:271\u20139. https:\/\/doi.org\/10.1177\/13872877251340084.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2338_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1612785","volume":"16","author":"J Forrest","year":"2025","unstructured":"Forrest J, Chen W, Jagadheesan K. Misuse and diversion of stimulant medications prescribed for the treatment of ADHD: a systematic review. Front Psychiatry. 2025;16:1612785. https:\/\/doi.org\/10.3389\/fpsyt.2025.1612785.","journal-title":"Front Psychiatry"},{"key":"2338_CR118","unstructured":"Freedland KE, Carney RM, Lenze EJ, Rich MW. Psychiatric and psychosocial aspects of cardiovascular disease. In: Braunwald\u2019s Heart Disease. 2025:Ch 13."},{"key":"2338_CR119","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.2014.14070889","volume":"172","author":"H Lavretsky","year":"2015","unstructured":"Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172:561\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14070889.","journal-title":"Am J Psychiatry"},{"key":"2338_CR120","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/gps.5536","volume":"36","author":"KR Smith","year":"2021","unstructured":"Smith KR, Kahlon CH, Brown JN, Britt RB. Methylphenidate use in geriatric depression: a systematic review. Int J Geriatr Psychiatry. 2021;36:1304\u201312. https:\/\/doi.org\/10.1002\/gps.5536.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2338_CR121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jagp.2019.08.011","volume":"28","author":"H Lavretsky","year":"2020","unstructured":"Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, et al. A randomized double-blind placebo-controlled trial of combined escitalopram and memantine for older adults with major depression and subjective memory complaints. Am J Geriatr Psychiatry. 2020;28:178\u201390. https:\/\/doi.org\/10.1016\/j.jagp.2019.08.011.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR122","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/a-1681-2047","volume":"55","author":"AA Maruf","year":"2022","unstructured":"Maruf AA, Poweleit EA, Brown LC, Strawn JR, Bousman CA. Systematic review and meta-analysis of L-methylfolate augmentation in depressive. Disord Pharmacopsychiatry. 2022;55:139\u201347. https:\/\/doi.org\/10.1055\/a-1681-2047.","journal-title":"Disord Pharmacopsychiatry"},{"key":"2338_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03317-3","volume":"15","author":"H Gong","year":"2025","unstructured":"Gong H, Su WJ, Deng SL, Luo J, Du ZL, Luo Y, et al. Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis. Transl Psychiatry. 2025;15:114. https:\/\/doi.org\/10.1038\/s41398-025-03317-3.","journal-title":"Transl Psychiatry"},{"key":"2338_CR124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jpsychires.2025.05.053","volume":"188","author":"R Moshfeghinia","year":"2025","unstructured":"Moshfeghinia R, Nemati H, Ebrahimi A, Shekouh D, Karami S, Eraghi MM, et al. The impact of probiotics, prebiotics, and synbiotics on depression and anxiety symptoms of patients with depression: a systematic review and meta-analysis. J Psychiatr Res. 2025;188:104\u201316. https:\/\/doi.org\/10.1016\/j.jpsychires.2025.05.053.","journal-title":"J Psychiatr Res"},{"key":"2338_CR125","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/j.1532-5415.2007.01292.x","volume":"55","author":"AY Dombrovski","year":"2007","unstructured":"Dombrovski AY, Lenze EJ, Dew MA, Mulsant BH, Pollock BG, Houck PR, Reynolds CF. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc. 2007;55:1325\u201332.","journal-title":"J Am Geriatr Soc"},{"key":"2338_CR126","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/jgp.0b013e3181ec8085","volume":"19","author":"RM Kok","year":"2011","unstructured":"Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19:249\u201355. https:\/\/doi.org\/10.1097\/jgp.0b013e3181ec8085.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR127","doi-asserted-by":"publisher","unstructured":"Brown EE, Rajji TK, Mulsant BH. Why do some older adults treated with antidepressants progress to dementia? J Clin Psychiatry. 2020;81. https:\/\/doi.org\/10.4088\/JCP.20com13559.","DOI":"10.4088\/JCP.20com13559"},{"key":"2338_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02414-0","volume":"20","author":"SE Morris","year":"2022","unstructured":"Morris SE, Sanislow CA, Pacheco J, Vaidyanathan U, Gordon JA, Cuthbert BN. Revisiting the seven pillars of RDoC. BMC Med. 2022;20:220. https:\/\/doi.org\/10.1186\/s12916-022-02414-0.","journal-title":"BMC Med"},{"key":"2338_CR129","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jagp.2015.05.010","volume":"24","author":"MA Pimontel","year":"2015","unstructured":"Pimontel MA, Rindskopf D, Rutherford BR, Brown PJ, Roose SP, Sneed JR. A meta-analysis of executive dysfunction and antidepressant treatment response in late-life depression. Am J Geriatr Psychiatry. 2015;24:31\u201341. https:\/\/doi.org\/10.1016\/j.jagp.2015.05.010.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR130","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11682-021-00494-9","volume":"16","author":"A Saberi","year":"2022","unstructured":"Saberi A, Mohammadi E, Zarei M, Eickhoff SB, Tahmasian M. Structural and functional neuroimaging of late-life depression: a coordinate-based meta-analysis. Brain Imaging Behav. 2022;16:518\u201331. https:\/\/doi.org\/10.1007\/s11682-021-00494-9.","journal-title":"Brain Imaging Behav"},{"key":"2338_CR131","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamapsychiatry.2022.0020","volume":"79","author":"J Wen","year":"2022","unstructured":"Wen J, Fu CHY, Tosun D, Veturi Y, Yang Z, Abdulkadir A, et al. Characterizing heterogeneity in neuroimaging, cognition, clinical symptoms, and genetics among patients with late-life depression. JAMA Psychiatry. 2022;79:464\u201374. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.0020.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR132","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jagp.2020.01.007","volume":"28","author":"VS Marshe","year":"2020","unstructured":"Marshe VS, Islam F, Maciukiewicz M, Bousman C, Eyre HA, Lavretsky H, et al. Pharmacogenetic implications for antidepressant pharmacotherapy in late-life depression: a systematic review of the literature for response, pharmacokinetics and adverse drug reactions. Am J Geriatr Psychiatry. 2020;28:609\u201329. https:\/\/doi.org\/10.1016\/j.jagp.2020.01.007.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR133","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/cpt.3162","volume":"115","author":"X Men","year":"2024","unstructured":"Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, et al. CYP2D6 phenotype influences pharmacokinetic parameters of venlafaxine: results from a population pharmacokinetic model in older adults with depression. Clin Pharm Ther. 2024;115:1065\u201374. https:\/\/doi.org\/10.1002\/cpt.3162.","journal-title":"Clin Pharm Ther"},{"key":"2338_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109867","volume":"100","author":"VS Marshe","year":"2020","unstructured":"Marshe VS, Islam F, Maciukiewicz M, Fiori LM, Yerko V, Yang J, et al. Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109867. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109867.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2338_CR135","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1176\/appi.ajp.2016.16050617","volume":"174","author":"VS Marshe","year":"2017","unstructured":"Marshe VS, Maciukiewicz M, Rej S, Tiwari AK, Sibille E, Blumberger DM, et al. Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults. Am J Psychiatry. 2017;174:468\u201375. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050617.","journal-title":"Am J Psychiatry"},{"key":"2338_CR136","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bpsgos.2021.07.008","volume":"2","author":"O Pain","year":"2022","unstructured":"Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe VS, Adams MJ, et al. Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci. 2022;2:115\u201326. https:\/\/doi.org\/10.1016\/j.bpsgos.2021.07.008.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"2338_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01248-3","volume":"11","author":"VS Marshe","year":"2021","unstructured":"Marshe VS, Maciukiewicz M, Hauschild AC, Islam F, Qin L, Tiwari AK, et al. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Transl Psychiatry. 2021;11:127. https:\/\/doi.org\/10.1038\/s41398-021-01248-3.","journal-title":"Transl Psychiatry"},{"key":"2338_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02532-0","volume":"13","author":"RA Wathra","year":"2023","unstructured":"Wathra RA, Men X, Elsheikh SSM, Marshe VS, Rajji TK, Lissemore JI, et al. Exploratory genome-wide analyses of cortical inhibition, facilitation, and plasticity in late-life depression. Transl Psychiatry. 2023;13:234. https:\/\/doi.org\/10.1038\/s41398-023-02532-0.","journal-title":"Transl Psychiatry"},{"key":"2338_CR139","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jpsychires.2019.04.017","volume":"114","author":"H Oughli","year":"2019","unstructured":"Oughli H, Lenze EJ, Locke AE, Yingling MD, Zhong Y, Miller JP, et al. Getting to precision psychopharmacology: combining clinical and genetic information to predict fat gain from aripiprazole. J Psychiatr Res. 2019;114:67\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.04.017.","journal-title":"J Psychiatr Res"},{"key":"2338_CR140","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3109\/15622975.2013.832380","volume":"15","author":"LD Garfield","year":"2014","unstructured":"Garfield LD, M\u00fcller DJ, Kennedy JL, Mulsant BH, Reynolds CF, Teitelbaum SL, et al. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World J Biol Psychiatry. 2014;15:404\u201310. https:\/\/doi.org\/10.3109\/15622975.2013.832380.","journal-title":"World J Biol Psychiatry"},{"key":"2338_CR141","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.psc.2023.02.008","volume":"46","author":"S Subramanian","year":"2023","unstructured":"Subramanian S, Oughli HA, Gebara MA, Palanca BJA, Lenze EJ. Treatment-resistant late-life depression: a review of clinical features, neuropsychology, neurobiology, and treatment. Psychiatr Clin North Am. 2023;46:371\u201389. https:\/\/doi.org\/10.1016\/j.psc.2023.02.008.","journal-title":"Psychiatr Clin North Am"},{"key":"2338_CR142","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1038\/s41380-020-0834-1","volume":"26","author":"CW Lin","year":"2021","unstructured":"Lin CW, Chang LC, Ma T, Oh H, French B, Puralewski R, et al. Older molecular brain age in severe mental illness. Mol Psychiatry. 2021;26:3646\u201356. https:\/\/doi.org\/10.1038\/s41380-020-0834-1.","journal-title":"Mol Psychiatry"},{"key":"2338_CR143","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jagp.2018.05.014","volume":"26","author":"EJ Lenze","year":"2018","unstructured":"Lenze EJ, Voineskos AN, Butters MA, Karp JF. Stopping cognitive decline in patients with late-life depression: a new front in the fight against dementia. Am J Geriatr Psychiatry. 2018;26:828\u201334. https:\/\/doi.org\/10.1016\/j.jagp.2018.05.014.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR144","doi-asserted-by":"publisher","unstructured":"Voineskos A, Zhukovsky P, Butters M, Lavretsky H, Brown P, Shimony J, et al. Brain-cognition relationships and treatment outcome in treatment-resistant late-life depression. Res. Sq. 2025; https:\/\/doi.org\/10.21203\/rs.3.rs-6340032\/v1.","DOI":"10.21203\/rs.3.rs-6340032\/v1"},{"key":"2338_CR145","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.xjmad.2023.100038","volume":"5","author":"WD Taylor","year":"2024","unstructured":"Taylor WD, Ajilore O, Karim HT, Butters MA, Krafty R, Boyd BD, et al. Assessing depression recurrence, cognitive burden, and neurobiological homeostasis in late life: design and rationale of the REMBRANDT study. J Mood Anxiety Disord. 2024;5:100038. https:\/\/doi.org\/10.1016\/j.xjmad.2023.100038.","journal-title":"J Mood Anxiety Disord"},{"key":"2338_CR146","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/da.22776","volume":"35","author":"MA Gebara","year":"2018","unstructured":"Gebara MA, Siripong N, DiNapoli EA, Maree RD, Germain A, Reynolds CF, et al. Effect of insomnia treatments on depression: a systematic review and meta-analysis. Depress Anxiety. 2018;35:717\u201331. https:\/\/doi.org\/10.1002\/da.22776.","journal-title":"Depress Anxiety"},{"key":"2338_CR147","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jagp.2023.03.009","volume":"31","author":"RL Rios","year":"2023","unstructured":"Rios RL, Kafashan M, Hyche O, Lenard E, Lucey BP, Lenze EJ, et al. Targeting slow wave sleep deficiency in late-life depression: a case series with propofol. Am J Geriatr Psychiatry. 2023;31:643\u201352. https:\/\/doi.org\/10.1016\/j.jagp.2023.03.009.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR148","doi-asserted-by":"publisher","first-page":"e087516","DOI":"10.1136\/bmjopen-2024-087516","volume":"14","author":"RL Rios","year":"2024","unstructured":"Rios RL, Green M, Smith SK, Kafashan M, Ching S, Farber NB, et al. Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial. BMJ Open. 2024;14:e087516. https:\/\/doi.org\/10.1136\/bmjopen-2024-087516.","journal-title":"BMJ Open"},{"key":"2338_CR149","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/m15-2175","volume":"165","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2016;165:125\u201333. https:\/\/doi.org\/10.7326\/m15-2175.","journal-title":"Ann Intern Med"},{"key":"2338_CR150","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5664\/jcsm.27286","volume":"4","author":"S Schutte-Rodin","year":"2008","unstructured":"Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487\u2013504.","journal-title":"J Clin Sleep Med"},{"key":"2338_CR151","doi-asserted-by":"crossref","unstructured":"National Institutes of Health. NIH state of the science conference statement on manifestations and management of chronic insomnia in Adults. Sleep. 2005;28:1049\u201357.","DOI":"10.1093\/sleep\/28.9.1049"},{"key":"2338_CR152","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jamapsychiatry.2021.3422","volume":"79","author":"MR Irwin","year":"2022","unstructured":"Irwin MR, Carrillo C, Sadeghi N, Bjurstrom MF, Breen EC, Olmstead R. Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial. JAMA Psychiatry. 2022;79:33\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3422.","journal-title":"JAMA Psychiatry"},{"key":"2338_CR153","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/mp.2014.76","volume":"20","author":"BS Diniz","year":"2015","unstructured":"Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F, et al. Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry. 2015;20:594\u2013601. https:\/\/doi.org\/10.1038\/mp.2014.76.","journal-title":"Mol Psychiatry"},{"key":"2338_CR154","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpsychires.2016.07.005","volume":"81","author":"SF Smagula","year":"2016","unstructured":"Smagula SF, Wallace ML, Anderson SJ, Karp JF, Lenze EJ, Mulsant BH, et al. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J Psychiatr Res. 2016;81:112\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.07.005.","journal-title":"J Psychiatr Res"},{"key":"2338_CR155","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jagp.2019.06.006","volume":"27","author":"AP Mendes-Silva","year":"2019","unstructured":"Mendes-Silva AP, Mwangi B, Aizenstein H, Reynolds CF 3rd, Butters MA, Diniz BS. Molecular senescence is associated with white matter microstructural damage in late-life depression. Am J Geriatr Psychiatry. 2019;27:1414\u20138. https:\/\/doi.org\/10.1016\/j.jagp.2019.06.006.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2338_CR156","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/geronb\/gbu096","volume":"69","author":"BS Diniz","year":"2014","unstructured":"Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Radanovic M, Gattaz WF, et al. Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. J Gerontol B Psychol Sci Soc Sci. 2014;69:845\u201351. https:\/\/doi.org\/10.1093\/geronb\/gbu096.","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"2338_CR157","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12129","volume":"7","author":"BS Diniz","year":"2021","unstructured":"Diniz BS, Vieira EM, Mendes-Silva AP, Bowie CR, Butters MA, Fischer CE, et al. Mild cognitive impairment and major depressive disorder are associated with molecular senescence abnormalities in older adults. Alzheimers Dement. 2021;7:e12129. https:\/\/doi.org\/10.1002\/trc2.12129.","journal-title":"Alzheimers Dement"},{"key":"2338_CR158","doi-asserted-by":"publisher","unstructured":"Schweiger A, Diniz B, Nicol G, Schweiger J, Dasklakis-Perez AE, Lenze EJ. Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders [version 1; peer review: 2 approved with reservations]. F1000Res. 2024;13. https:\/\/doi.org\/10.12688\/f1000research.151963.1.","DOI":"10.12688\/f1000research.151963.1"}],"updated-by":[{"DOI":"10.1038\/s41386-026-02387-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02338-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:38:39Z","timestamp":1773902319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02338-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":158,"alternative-id":["2338"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02338-w","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: figure legend and section title have been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41386-026-02387-1","URL":"https:\/\/doi.org\/10.1038\/s41386-026-02387-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Lenze has received research support from the Patient Centered Outcomes Research Center (PCORI), COVID Early Treatment Fund, Mercatus Center Emergent Ventures, Balvi Philanthropic Fund, Pritikin, and the XPrize Foundation. Dr. Karp receives research support from Johnson & Johnson Neuroscience. He has served as a scientific advisor for Johnson & Johnson Neuroscience, Otsuka, Biogen, and Aifred Health. He receives support from NIH, the Patient Centered Outcomes Research Center (PCORI), and HRSA. Dr. Gebara has received compensation from Otsuka for developing and presenting a disease-state webinar and research support from Janssen. Dr. Nicol has served as a Co-Investigator or Principal Investigator for studies funded by COMPASS Pathways, LB Pharmaceuticals, Inc., Alkermes, and Usona Institute (drug only). She has served as a consultant for Carelon. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received with the past 5 years, research support from Brain Canada, the Canadian Institutes of Health Research (CIHR), the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation) and HAPPYneuron (software used in a study founded by Brain Canada).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}